Effect of DASH Diet and Progressive Muscle Relaxation on Cardiovascular Risks in Postmenopausal Women
NCT ID: NCT06600347
Last Updated: 2024-09-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
90 participants
INTERVENTIONAL
2024-06-10
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Hot Flashes and Neurovascular Function in Women
NCT05193968
Age Comparisons of Exercising Muscle O2 Supply in Healthy Adults: Effects of Esmolol Infusion
NCT04181606
Sex-related Differences in Sympathetic Vascular Transduction in the Setting of Hypoxemia
NCT05256069
Aging, Beta Blockers, and Thermoregulatory Responses
NCT06582680
Race, Natriuretic Peptides and Physiological Perturbations
NCT03070184
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A variety of non-pharmacologic treatments to manage stress have been found effective in reducing blood pressure and the development of hypertension. The DASH eating pattern promotes blood pressure reduction by encouraging the consumption of foods that are low in saturated fat, total fat, cholesterol, and sodium and high in potassium, calcium, magnesium, fiber, and protein. In terms of actual food choices, the DASH eating pattern encourages whole grains, fat free or low-fat dairy products, fruits, vegetables, poultry, fish, and nuts. Foods that are limited include fatty meats, full-fat dairy products, tropical oils (e.g., coconut, palm, and palm kernel oils), and sweets and sugar sweetened beverages.
The mechanism by which relaxation techniques lower blood pressure is unclear. One theory suggests that they may help lower the stress and physiologic arousal produced by the autonomic nervous system, thereby reducing blood pressure. So this study is a trial to determine the effect of DASH diet and progressive muscle relaxation in reducing cardiovascular risks in postmenopausal women.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DASH diet group
The participants will be treated with the DASH diet and antihypertensive drugs
DASH diet
The participants will be treated with the DASH diet (1600-1800 calories/ day) for three months, in addition to antihypertensive drugs.
Anti hypertensive drugs
All participants in all groups will be treated with antihypertensive drugs as prescribed from the physician
Progressive muscle relaxation group
The participants will be treated with progressive muscle relaxation and antihypertensive drugs
Progressive muscle relaxation
The participants will be treated with progressive muscle relaxation for 30 minutes, 3 times/week for 3 months, in addition to antihypertensive drugs.
Anti hypertensive drugs
All participants in all groups will be treated with antihypertensive drugs as prescribed from the physician
DASH diet and progressive muscle relaxation group
The participants will be treated with DASH diet and progressive muscle relaxation in addition to antihypertensive drugs
DASH diet
The participants will be treated with the DASH diet (1600-1800 calories/ day) for three months, in addition to antihypertensive drugs.
Progressive muscle relaxation
The participants will be treated with progressive muscle relaxation for 30 minutes, 3 times/week for 3 months, in addition to antihypertensive drugs.
Anti hypertensive drugs
All participants in all groups will be treated with antihypertensive drugs as prescribed from the physician
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DASH diet
The participants will be treated with the DASH diet (1600-1800 calories/ day) for three months, in addition to antihypertensive drugs.
Progressive muscle relaxation
The participants will be treated with progressive muscle relaxation for 30 minutes, 3 times/week for 3 months, in addition to antihypertensive drugs.
Anti hypertensive drugs
All participants in all groups will be treated with antihypertensive drugs as prescribed from the physician
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Their body mass index will be ranged from 30-35 kg/m2.
* All women are hypertensive at least one year postmenopause.
* Their scores in perceived stress scale will be ranged from 14-40.
Exclusion Criteria
* Women who have other known causes of hypertension, such as renal diseases.
* Women who are using sedatives or tranquilizer or antidepressant drugs.
50 Years
60 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cairo University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Farahnaz Ahmed Mohamed
Principal investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mohamed Awad, professor
Role: STUDY_DIRECTOR
Cairo University
Heba Abdel Halim, PHD
Role: STUDY_DIRECTOR
National Institute of Nutrition
Hala Emara, professor
Role: STUDY_CHAIR
Cairo University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Farahnaz Ahmed Mohamed
Suez, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P.T.REC/012/004059
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.